MX2017011392A - P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su metodo de preparacion. - Google Patents

P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su metodo de preparacion.

Info

Publication number
MX2017011392A
MX2017011392A MX2017011392A MX2017011392A MX2017011392A MX 2017011392 A MX2017011392 A MX 2017011392A MX 2017011392 A MX2017011392 A MX 2017011392A MX 2017011392 A MX2017011392 A MX 2017011392A MX 2017011392 A MX2017011392 A MX 2017011392A
Authority
MX
Mexico
Prior art keywords
toluenesulfonate
preparation
method therefor
crystal form
kinase inhibitor
Prior art date
Application number
MX2017011392A
Other languages
English (en)
Inventor
Wu Guaili
Gao Xiaohui
Bian Lin
JIA Junlei
Original Assignee
Jiangsu Hengrui Medicine Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2017011392A publication Critical patent/MX2017011392A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

Se describe un p-toluensulfonato para un inhibidor de MEK cinasa, y una forma de cristal del mismo y un método de preparación del mismo. De manera específica, se describe p-toluensulfonato de 2-((2-fluorine-4-yodofenil)amino)-1-metil-4-((6-metilpiridin-3-gr upo)oxigrupo)-6-carbonil-1,6-dihidropiridin-3-formamida (un compuesto representado por la fórmula (I)), y una forma de cristal I y un método de preparación del mismo. La forma de cristal I obtenida del compuesto representada por la fórmula (I) tiene buena estabilidad de forma de cristal y estabilidad química, y un solvente de cristalización usado tiene baja toxicidad y bajo residuo y puede usarse mejor en el tratamiento clínico. (ver Fórmula).
MX2017011392A 2015-03-27 2016-03-08 P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su metodo de preparacion. MX2017011392A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510141303 2015-03-27
PCT/CN2016/075853 WO2016155473A1 (zh) 2015-03-27 2016-03-08 一种mek激酶抑制剂的对甲苯磺酸盐、其结晶形式及制备方法

Publications (1)

Publication Number Publication Date
MX2017011392A true MX2017011392A (es) 2018-01-15

Family

ID=57005438

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017011392A MX2017011392A (es) 2015-03-27 2016-03-08 P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su metodo de preparacion.

Country Status (12)

Country Link
US (2) US10118911B2 (es)
EP (1) EP3275866B1 (es)
JP (1) JP2018509407A (es)
KR (1) KR20170131506A (es)
CN (1) CN106795116B (es)
AU (1) AU2016239028B2 (es)
BR (1) BR112017018580A2 (es)
CA (1) CA2978796A1 (es)
MX (1) MX2017011392A (es)
RU (1) RU2704251C2 (es)
TW (1) TWI705060B (es)
WO (1) WO2016155473A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019535696A (ja) 2016-11-25 2019-12-12 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． ピリドン誘導体の医薬組成物およびその製造方法
CN108884048B (zh) * 2016-12-01 2021-07-27 江苏恒瑞医药股份有限公司 一种吡啶酮类衍生物的制备方法及其中间体
CN113423398A (zh) * 2019-01-29 2021-09-21 贝达药业股份有限公司 Mek抑制剂及其在医药上的应用
TW202114994A (zh) * 2019-07-29 2021-04-16 大陸商江蘇恆瑞醫藥股份有限公司 一種１，６－二氫吡啶－３－甲醯胺衍生物的製備方法
US11878958B2 (en) 2022-05-25 2024-01-23 Ikena Oncology, Inc. MEK inhibitors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1272290B (it) * 1994-06-20 1997-06-16 Avantgarde Spa Sale della l-carnitina e composizioni farmaceutiche che lo contengono per il trattamento di affezioni cutanee
US7732616B2 (en) * 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
WO2009129938A1 (en) * 2008-04-22 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Substituted phenoxybenzamides
CN107011345A (zh) * 2008-12-23 2017-08-04 勃林格殷格翰国际有限公司 有机化合物的盐形式
CN102459188A (zh) 2009-06-15 2012-05-16 凯美隆(北京)药业技术有限公司 新型6-芳氨基吡啶酮磺酰胺和6-芳氨基吡嗪酮磺酰胺mek抑制剂
US20120238599A1 (en) 2011-03-17 2012-09-20 Chemizon, A Division Of Optomagic Co., Ltd. Heterocyclic compounds as mek inhibitors
WO2014204263A1 (en) * 2013-06-20 2014-12-24 The Asan Foundation Substituted pyridinone compounds as mek inhibitors
CN104936945B (zh) * 2013-10-25 2017-11-03 上海恒瑞医药有限公司 吡啶酮类衍生物、其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
US20180370948A1 (en) 2018-12-27
JP2018509407A (ja) 2018-04-05
AU2016239028B2 (en) 2019-09-19
CN106795116A (zh) 2017-05-31
RU2017134709A3 (es) 2019-07-17
TWI705060B (zh) 2020-09-21
TW201634459A (zh) 2016-10-01
WO2016155473A1 (zh) 2016-10-06
BR112017018580A2 (pt) 2018-04-24
RU2017134709A (ru) 2019-04-29
EP3275866A1 (en) 2018-01-31
EP3275866B1 (en) 2019-12-04
US10118911B2 (en) 2018-11-06
RU2704251C2 (ru) 2019-10-25
EP3275866A4 (en) 2018-08-15
AU2016239028A1 (en) 2017-09-14
US20180118715A1 (en) 2018-05-03
KR20170131506A (ko) 2017-11-29
CN106795116B (zh) 2019-11-01
CA2978796A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
PH12017502090A1 (en) Heterocyclic amides as kinase inhibitors
MX2017011392A (es) P-toluensulfonato para inhibidor de mek cinasa, y su forma de cristal y su metodo de preparacion.
SV2017005467A (es) Formas sólidas de un inhibidor ask1.
MX2018008131A (es) Forma cristalina del inhibidor de la btk quinasa y metodo de preparacion de la misma.
SG10201805628TA (en) Deuterated heterocyclic compounds and their use as imaging agents
TW201613886A (en) 3-amino-1,5,6,7-tetrahydro-4h-indol-4-ones
MY188447A (en) Indazole compounds as fger kinase inhibitor, preparation and use thereof
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
MX2015010837A (es) Compuestos de antranilamida, sus mezclas y el uso de los mismos como pesticidas.
MY194116A (en) Pharmaceutical compounds
EA201690127A1 (ru) Состав на основе ингибиторов syk
SG10201804026WA (en) Inhibitors of influenza viruses replication
MX2016002794A (es) Compuestos antiproliferativos.
MX2018003554A (es) Benzamidas sustituidas con isoxazolina y analogos como insecticidas.
MX2017009270A (es) Hidroxietil sulfonato de inhibidor de proteina cinasa dependiente de ciclina, su forma cristalina y su metodo de preparacion.
MX2016004963A (es) Sal y formas cristalinas de inhibidores de quinasa tipo polo-4.
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
MX2016007810A (es) Derivados de n1-(3,3,3-trifluoro-2-hidroxo-2-metilpropionil)-piper idina como inhibidores de piruvato deshidrogenasa cinasa.
MX2015013365A (es) Derivados de urea y su uso como inhibidores de proteina de union de acidos grasos (puag).
MY185367A (en) Improved process for the preparation of osimertinib (azd9291) or a salt thereof, and ?azd9291 aniline? or a salt thereof
TW201612165A (en) Preparation method for aromatic heterocyclic compound used as selective jak3 and/or jak1 kinase inhibitor and application of aromatic heterocyclic compound
MX2018004055A (es) Compuestos de imino con un sustituyente de 2-cloropirimidin-5-ilo como agentes de control de plagas.
PH12016501704A1 (en) Method for producing 2-acyliminopyridine derivative